XEROFORM

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT KSENOFORM (XEROFORM)

Composition:

Active substance: bismuth tribromophenate;

1 container contains 7 g of bismuth tribromophenate (xeroform);

1 polymer bottle with a nozzle contains 10 g of bismuth tribromophenate (xeroform).

Pharmaceutical form. Topical powder.

Main physicochemical properties: amorphous yellow powder with a faint specific odor.

Pharmacotherapeutic group. Antiseptics and disinfectants. ATC code D08A X.

Pharmacological properties.

Bismuth tribromophenate (xeroform) has antiseptic, astringent, and drying properties. The action of the drug is based on its interaction with tissue proteins, forming albuminates that protect sensitive nerve endings from irritation by creating a protective film. Additionally, it causes vasoconstriction, reduces vascular permeability (decreasing exudation), and inhibits enzymes. Interaction with microbial proteins suppresses their vital activity.

Clinical characteristics.

Indications.

As an astringent, drying, and antiseptic agent in inflammatory skin diseases.

Contraindications.

Increased individual sensitivity.

Interaction with other medicinal products and other types of interactions.

Not established.

Special precautions.

Avoid contact of the product with the eyes.

Use during pregnancy or breastfeeding.

There are no data on the use of the product during pregnancy or breastfeeding; therefore, the product should be prescribed only when, in the opinion of the physician, the expected benefit to the mother outweighs the potential risk to the fetus or infant.

Ability to influence reaction rate when driving vehicles or operating machinery.

Has no effect.

Method of Administration and Dosage

For external use only. Apply the powder to the affected areas of the skin. The duration of treatment depends on the course of the disease and is determined individually by a physician.

Children.

The efficacy and safety of the drug in children have not been established. For this reason, its use is possible only under medical supervision and on a physician's prescription.

Overdose.

No data available.

Side effects.

Not observed.

If any adverse reactions occur, treatment should be discontinued and medical advice should be sought.

Shelf life.

5 years.

Storage conditions.

Store at a temperature not exceeding +30 °C, in a place inaccessible to children.

Packaging.

7 g of powder in a container.

10 g of powder in a polymer bottle with a dispenser, 1 polymer bottle in a cardboard box.

Prescription status.

Over-the-counter.

Manufacturer.

LLC "Istok-Plus".

Manufacturer's address and place of business.

Ukraine, 69032, Zaporizhzhia, Makarenka St., 4.